Meeting
2015 ASCO Annual Meeting
Long-term safety profile of palbociclib (P) in combination with letrozole (L) as first-line treatment for postmenopausal patients with ER+ and HER2- advanced breast cancer (ABC) (PALOMA-1/TRIO-18).
Authors
Dennis J. Slamon
School of Medicine/Translational Oncology Research Laboratory, University of California, Los Angeles, Los Angeles, CA
Dennis J. Slamon , John Crown , Istvan Lang , Sergey O. Kulyk , Marcus Schmidt , Ravi Patel , Anu Thummala , Nataliya L. Voytko , Sophia Randolph , Sindy Kim , Xin Huang , Cynthia Huang Bartlett , Patrick Schnell , Richard S. Finn
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—HER2/ER
Track
Breast Cancer
Sub Track
ER+
Clinical Trial Registration Number
NCT00721409
Citation
J Clin Oncol 33, 2015 (suppl; abstr 570)
DOI
10.1200/jco.2015.33.15_suppl.570
Abstract #
570
Poster Bd #
58
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Clinical efficacy and safety profile of palbociclib (P) in combination with letrozole (L) as first-line treatment in patients (pts) with ER+ and HER2- advanced breast cancer (ABC) who have not received any systemic treatment (ST): A subgroup analysis of PALOMA-1/TRIO-18.
First Author: Richard S. Finn
Poster
2015 ASCO Annual Meeting
Efficacy and safety of first-line palbociclib plus letrozole compared with letrozole alone in patients aged ≥ 65 years with estrogen receptor-positive, HER2-negative advanced breast cancer: A subgroup analysis by age of the PALOMA-1/TRIO-18 trial.
First Author: John Crown
Poster
2019 ASCO Annual Meeting
First-line (1L) ribociclib (RIB) plus letrozole (LET) for postmenopausal women with hormone receptor-positive (HR+), HER2- advanced breast cancer (ABC): MONALEESA-2 long-term safety results.
First Author: Joyce O'Shaughnessy
Poster
2017 ASCO Annual Meeting
First-line ribociclib plus letrozole for postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC): MONALEESA-2 safety results.
First Author: Wolfgang Janni